{"id":"https://openalex.org/W3382729","doi":null,"title":"Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.","display_name":"Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.","alternate_titles":[],"publication_year":2000,"publication_date":"2000-09-01","ids":{"openalex":"https://openalex.org/W3382729","mag":"3382729","pmid":"https://pubmed.ncbi.nlm.nih.gov/11062756"},"language":"en","primary_location":{"id":"pmid:11062756","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11062756","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W3382729"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110402921","display_name":"Yoshinori Nio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405285000","display_name":"Shimane Medical University","ror":"https://ror.org/04kg5pk90","country_code":"JP","type":"education","lineage":["https://openalex.org/I169016828","https://openalex.org/I4405285000"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Y Nio","raw_affiliation_strings":["First Department of Surgery, Shimane Medical University, Izumo, Japan. fsurgery@shimane-med.ac.jp"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Surgery, Shimane Medical University, Izumo, Japan. fsurgery@shimane-med.ac.jp","institution_ids":["https://openalex.org/I4405285000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084372818","display_name":"Noriyuki Hirahara","orcid":"https://orcid.org/0000-0001-8684-6098","observed_orcids":["https://orcid.org/0000-0001-8684-6098"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N Hirahara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029433754","display_name":"Yoshimitsu Minari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y Minari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024230492","display_name":"Chikage Iguchi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C Iguchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067555011","display_name":"Kunihiro Yamasawa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Yamasawa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090254658","display_name":"Tomoko Toga","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Toga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"K Tamura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Tamura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.00012158,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"20","issue":"5A","first_page":"3293","last_page":"3299"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.7889999747276306},{"id":"https://openalex.org/keywords/mhc-class-i-expression","display_name":"MHC class I expression","score":0.8690000176429749},{"id":"https://openalex.org/keywords/tumor-surface-antigens","display_name":"tumor surface antigens","score":0.625},{"id":"https://openalex.org/keywords/h-2dd","display_name":"H-2Dd","score":0.7739999890327454},{"id":"https://openalex.org/keywords/h-2kd","display_name":"H-2Kd","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-rejection","display_name":"tumor rejection","score":0.5540000200271606},{"id":"https://openalex.org/keywords/anti-t-cell-monoclonal-antibodies","display_name":"anti-T cell monoclonal antibodies","score":0.7409999966621399},{"id":"https://openalex.org/keywords/soluble-tumor-antigens","display_name":"soluble tumor antigens","score":0.5649999976158142},{"id":"https://openalex.org/keywords/tumor-immunogenicity","display_name":"tumor immunogenicity","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C2778964538","wikidata":"https://www.wikidata.org/wiki/Q2090167","display_name":"Plasmacytoma","level":3,"score":0.7071991562843323},{"id":"https://openalex.org/C2776495794","wikidata":"https://www.wikidata.org/wiki/Q1362453","display_name":"Fibrosarcoma","level":2,"score":0.646975040435791},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.6354689598083496},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.591426432132721},{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.544533908367157},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5234394073486328},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4824303090572357},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4679996371269226},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40997564792633057},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3832798898220062},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2622339725494385},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.127208411693573},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08343932032585144},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000949","descriptor_name":"Histocompatibility Antigens Class II","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002458","descriptor_name":"Cell Fractionation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006183","descriptor_name":"H-2 Antigens","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D008212","descriptor_name":"Lymphocyte Depletion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008285","descriptor_name":"Major Histocompatibility Complex","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010954","descriptor_name":"Plasmacytoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010954","descriptor_name":"Plasmacytoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D014611","descriptor_name":"Vaccination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064532","descriptor_name":"Histocompatibility Antigen H-2D","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:11062756","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11062756","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},{"id":"mag:3382729","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11062756","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2031893392","https://openalex.org/W1989369730","https://openalex.org/W2034476737","https://openalex.org/W2094821674","https://openalex.org/W1970732779","https://openalex.org/W1996581317","https://openalex.org/W2328819671","https://openalex.org/W2329657383","https://openalex.org/W1714525571","https://openalex.org/W2053228897"],"abstract_inverted_index":{"Chemotherapy":[0],"sometimes":[1],"results":[2],"in":[3,20,102,145,162,170],"induction":[4,16],"of":[5,17,33,38,125,201,213,232],"specific":[6],"antitumor":[7,18,193,226],"immunity.":[8,194],"We":[9],"investigated":[10],"the":[11,15,31,36,41,76,126,199,230],"mechanisms":[12],"responsible":[13],"for":[14,142],"immunity":[19,227],"mice":[21,45,77,115,127,135,163],"bearing":[22],"MOPC-104E":[23,51,98,147,159,167,179],"plasmacytoma":[24],"after":[25,209],"chemotherapy":[26],"with":[27,50,60,82,138,165,173],"cisplatin":[28],"(CDDP),":[29],"especially":[30],"effects":[32],"CDDP":[34,61,117,223],"on":[35,40,53,65,72,119,149],"expression":[37,200,231],"MHC":[39],"tumor":[42,129],"surface.":[43],"BALB/c":[44,114,134],"were":[46,110,130,136],"subcutaneously":[47],"(s.c.)":[48],"inoculated":[49,137],"cells":[52,148,168,180],"day":[54,66,73,120,150],"0,":[55,151],"then":[56],"intravenously":[57],"(i.v.)":[58],"treated":[59],"at":[62],"3.6":[63],"mg/kg":[64],"7.":[67],"The":[68,91,155],"tumors":[69,92],"disappeared":[70],"completely":[71],"35":[74],"and":[75,153,182,186,205,217],"rejected":[78],"a":[79],"second":[80],"challenge":[81],"MOPC-104E,":[83],"but":[84,211],"did":[85,93],"not":[86,94],"reject":[87,158],"syngeneic":[88],"Meth-A":[89],"fibrosarcoma.":[90],"regress,":[95],"however,":[96],"when":[97,106],"was":[99,160,207,219],"s.c.":[100],"transplanted":[101],"nude":[103],"mice,":[104],"or":[105,128,177],"anti-T-cell":[107],"monoclonal":[108],"antibodies":[109],"i.v.":[111],"injected":[112],"into":[113,184],"before":[116],"treatment":[118],"6.":[121],"To":[122],"determine":[123],"which":[124],"affected":[131],"by":[132,189,228],"CDDP,":[133],"CDDP-treated":[139,174,176],"(12.5":[140],"micrograms/ml":[141],"3":[143],"hours":[144],"vitro)":[146],"7":[152],"14.":[154],"potential":[156],"to":[157],"lower":[161],"immunized":[164,172],"ethanol-treated":[166],"than":[169],"those":[171],"cells.":[175],"-untreated":[178],"ultrasonicated":[181],"fractionated":[183],"soluble":[185],"insoluble":[187],"fractions":[188],"centrifuging,":[190],"also":[191],"induced":[192,224],"Flow":[195],"cytometry":[196],"demonstrated":[197],"that":[198,212,222],"MHC-class-I":[202,233],"antigens":[203,215],"H-2Dd":[204],"H-2Kd":[206],"enhanced":[208],"CDDP-treatment,":[210],"class-II":[214],"I-Ad":[216],"I-Ed":[218],"not,":[220],"suggesting":[221],"tumor-specific":[225],"enhancing":[229],"antigens.":[234]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3382729","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
